Follow news, literature and expert opinions on GLP-1 as emerging target in the management of T2DM & Cardiovascular Disease
In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
Download the meeting impression of this PACE symposium during Heart Failure 2018, which considered what recent outcome trials with glucose-lowering trials can tell us about us about optimal management of patients with HF and diabetes.
Prof. Zannad compared the clinical outcomes in trials of various novel classes of glucose-lowering drugs, to postulate what these findings may tell us about their mechanism of action, and how they can be benefitted from in the management of patients with HF and diabetes.
Download the meeting impression of this PACE symposium during EuroPrevent 2018, that considered how to apply novel outcome data with GLP-1 RA to clinical practice.
This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.
Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.
Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.
In the PIONEER 1 and 3 phase 3a trials, oral semaglutide reduced HbA1c and body weight in T2DM patients compared to placebo or sitagliptin.
In a phase 2a study, MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.